Table 2.
II-IV GVHD | III-IV GVHD | CIR | NRM | LFS | ||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | |||||||||||||||||||||
HR | 95% Cl | p value | HR | 95% Cl | p value | HR | 95% Cl | p value | HR | 95% Cl | p value | HR | 95% Cl | p value | HR | 95% Cl | p value | HR | 65% Cl | p value | HR | 65% Cl | p value | HR | 65% Cl | p value | HR | 65% Cl | p value | |
Age(≥14 vs. <14yrs) | 0.785 | 0.395-1.56 | 0.49 | 0.339 | 0.0921-1.25 | 0.088 | 0.506 | 0.1081-2.37 | 0.39 | 1.23 | 0.418-3.62 | 0.708 | 2.09 | 0.89-4.91 | 0.084 | 1.8 | 0.921-3.51 | 0.079 | 1.652 | 0.84-3.25 | 0.15 | |||||||||
Treatment pre-HSCT (CAR-T vs. control) | 2.36 | 1.18-4.75 | 0.016 | 0.956 | 0.263-3.47 | 0.945 | 0.873 | 0.241-3.17 | 0.836 | 0.791 | 0.295-2.12 | 0.641 | 0.827 | 0.38-1.8 | 0.631 | |||||||||||||||
Disease status(≥CR2 vs. CR 1) | 1.09 | 0.557-2.15 | 0.769 | 0.494 | 0.152-1.6 | 0.239 | 3.87 | 1.09-13.7 | 0.027 | 4.1 | 1.13-14.84 | 0.031 | 0.774 | 0.344-1.74 | 0.54 | 1.54 | 0.808-2.93 | 0.192 | ||||||||||||
MRD(pos vs. neg) | 1.09 | 0.536-2.23 | 0.81 | 2.29 | 0.75-7.02 | 0.142 | 2.81 | 0.961-8.24 | 0.056 | 3.02 | 1.02-8.96 | 0.046 | 1.45 | 0.638-3.32 | 0.38 | 2.21 | 1.16-4.24 | 0.017 | 2.105 | 1.09-4.06 | 0.027 | |||||||||
Poor risk chromosomes (yes vs. no) | 1.5 | 0.76-2.95 | 0.245 | 2.48 | 0.735-8.17 | 0.125 | 0.709 | 0.236-2.13 | 0.543 | 0.622 | 0.263-1.47 | 0.271 | 0.614 | 0.313-1.21 | 0.151 | |||||||||||||||
Conditioning(TBI-based vs. Bu-based) | 0.888 | 0.365-2.16 | 0.795 | 0.254 | 0.0815-8.17 | 0.015 | 0.387 | 0.0929-1.61 | 0.19 | 0.655 | 0.181-2.38 | 0.523 | 0.937 | 0.314-2.79 | 0.903 | 0.883 | 0.384-2.03 | 0.765 | ||||||||||||
Donor type (haplo vs. MUD/MSD) | 0.894 | 0.45-1.78 | 0.753 | 3.17 | 0.715-14 | 0.113 | 1.33 | 0.413-4.31 | 0.629 | 0.917 | 0.402-2.09 | 0.84 | 1.25 | 0.646-2.42 | 0.516 | |||||||||||||||
donor-recipients gender matched(female to male vs. others) | 1.16 | 0.464-2.89 | 0.761 | 3.37 | 1.07-10.6 | 0.0375 | 1.885 | 0.4163-8.54 | 0.41 | 1.15 | 0.271-4.89 | 0.853 | 0.586 | 0.142-2.42 | 0.457 | 0.61 | 0.234-1.59 | 0.33 | ||||||||||||
course from diagnosis to transplant (≥ median vs. <median) | 0.883 | 0.45-1.73 | 0.719 | 0.455 | 0.141-1.47 | 0.188 | 2.34 | 0.732-7.48 | 0.144 | 0.6 | 0.262-1.37 | 0.225 | 1.05 | 0.552-1.98 | 0.893 | |||||||||||||||
MNC (≥median vs. <median) | 0.59 | 0.303-1.15 | 0.3 | 0.996 | 0.351-2.82 | 0.934 | 1.11 | 0.412-3 | 0.886 | 0.926 | 0.433-1.98 | 0.871 | 1.12 | 0.62-2.01 | 0.616 | |||||||||||||||
CD3 (≥median vs. <median) | 1.17 | 0.596-2.29 | 0.655 | 0.713 | 0.228-2.23 | 0.561 | 0.421 | 0.13-1.36 | 0.137 | 1.13 | 0.506-2.53 | 0.766 | 0.824 | 0.432-1.57 | 0.559 | |||||||||||||||
CD34 (≥median vs. <median) | 1.01 | 0.511-1.98 | 0.986 | 0.682 | 0.219-2.12 | 0.51 | 0.413 | 0.129-1.32 | 0.128 | 0.916 | 0.408-2.06 | 0.834 | 0.576 | 0.303-1.1 | 0.096 | 0.644 | 0.34-1.22 | 0.18 | ||||||||||||
cGVHD (limited vs. extensive vs. |